



**Microbial resistance of polymyxin and its potential underlying mechanism(s)  
among Gram-negative bacteria recovered from nosocomial infections in  
Egypt**

**A Thesis**

Submitted in Partial Fulfillment of the Requirements for the

**Master's degree**

In Pharmaceutical Sciences

**(Microbiology and Immunology)**

By

**Amani Thaer Abdulzahra Quraishi**

Bachelor of Pharmaceutical Sciences

Faculty of Pharmacy, Misr University for Science and Technology, 2014

Under Supervision of

**Prof. Dr. Walid Faisal Ahmed Elkhatab, PhD**

Professor of Microbiology and Immunology,

Faculty of Pharmacy, Ain Shams University

**Dr. Mahmoud Abdel-Ati Fouad Khalil, PhD**

Lecturer of Microbiology and Immunology,

Faculty of Pharmacy, Al-Fayoum University.

**2019**



## ACKNOWLEDGMENTS

First and foremost, all thanks and praises to Allah, as he gave me the strength to continue this path with all ups and downs that have faced me along the way.

I would first like to express my deepest gratitude **Prof. Dr. Walid Faisal Elkhatib**, Professor of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, the door to Prof. **Elkhatib** office was always open whenever I ran into a trouble spot or had a question about my research or writing. He consistently allowed this paper to be my own work, but steered me in the right the direction whenever he thought I needed it.

There are no enough words to thank **Dr. Mahmoud Abdel-Ati Fouad Khalil**, lecturer of Microbiology and Immunology, faculty of pharmacy, Al-Fayoum University, as you always had my back through this entire time and suggesting the point of my research, planning the work, scientific supervision, valuable discussions and constructive criticism throughout this study.

A special thanks to **Dr. Abdelbary Prince**, Associated Professor of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Cairo university, and founder of EgyptBiolabs, for his help and offering all the Lab. Facilities.

I also would like to thank everyone who were involved in the validation for this research as without their passionate participation and input, this study could not have been successfully conducted.

**Finally**, my deepest everlasting thanks and appreciation are for my beloved **dad, mom**, and **siblings** who have never failed to give me support and encouragement throughout my life. And I would like to take this opportunity to thank my **friends**, specially **Dr. Lubna Ali** for their continuous support and prayers that truly helped me to accomplish this work.

والحمد لله كما ينبغي لجلال وجهه وعظيم سلطانه.

*Amani T. Abdulzahra.*



# LIST OF CONTENTS

ACKNOWLEDGMENTS.....	II.
LIST OF CONTENTS.....	III.
LIST OF ABBREVIATIONS.....	VII.
LIST OF FIGURES.....	X.
LIST OF TABLES.....	XII.
ABSTRACT.....	13
INTRODUCTION.....	16
AIM OF WORK.....	17
LITERATURE REVIEW.....	20
1. Nosocomial Infections.....	21
2. Types of Nosocomial Infections.....	22
2.1. Central line-associated bloodstream infections .....	22
2.2. Resistance in Gram-negative Bacteria.....	22
2.3.Surgical Site Infections.....	22
2.4.Ventolator Associated Pneumonia .....	23
3. Most common bacterial microorganisms that cause nosocomial infections	23
4. Epidemiology of Nosocomial Infections.....	24
5. <i>Acinetobacter baumannii</i> .....	26
6. Genus <i>Acinetobacter</i> .....	27
7. Natural Habitat.....	28
8. Virulence Factors.....	28
9. Diseases caused by <i>A. baumannii</i> .....	29
9.1. Hospital-acquired Pneumonia.....	30
9.2. Community-acquired Pneumonia.....	30
9.3. Bloodstream Infections.....	30

9.4. Urinary Tract Infections.....	31
9.5. Meningitis.....	30
9.6. Other Manifestations .....	30
10. <i>A. baumannii</i> Antibiotic Resistance Mechanisms.....	31
11. Antimicrobial Inactivating Enzymes.....	33
11.1. Porins Channels and Other Outer Membrane Proteins .....	36
11.2. Mutations that Change Cellular or Targets Functions.....	37
12. Therapeutic Options.....	38
12.1. Polymyxin.....	41
MATERILS AND METHMETHODS.....	45
I. MATERIALS.....	46
1. Bacterial Isolates.....	46
1.1. Reference Microorganism.....	46
2. Bacterial Identification.....	46
3. Chemicals.....	46
4. Media and Media Ingredients.....	48
5. Buffers, Solutions and Reagents.....	49
6. Anti-biogram Analysis of <i>A. baumannii</i> Isolates Against some Antimicrobial Agents.....	52
6.1. Antimicrobial Susceptibility Test Disk Diffusion Method.....	52
6.2. Minimum Inhibitory Concentrations (MICs).....	52

7. Equipment.....	53
<b>II. Methods.....</b>	<b>55</b>
1. Identification of Bacterial Isolates and Microscope examination and morphology.....	55
2. Anti-biogram Analysis of <i>A. baumannii</i> Isolates Against some Antimicrobial Agents.....	55
2.1. Antimicrobial Susceptibility Testing.....	55
2.2. Minimum Inhibitory Concentrations MICs.....	56
3. $\beta$ -Lactamase assays.....	56
3.1. Modified Hodge test (MHT).....	56
3.2. Imipenem-EDTA double-disk synergy test.....	56
4. DNA Extraction.....	57
5. Agarose Gel Preparation.....	58
6. Polymerase Chain Reaction (PCR).....	59
7. Primers Used in this Study.....	60
8. PCR Protocol.....	61
8.1. Investigation of Colistin Resistant Genes	61
8.2. Detection of Carbapenem-hydrolyzing $\beta$ -lactamase genes.....	61
8.3. Detection of 16S rRNA methylase genes.....	61
<b>RESULTS</b>	<b>62</b>
1. Identification of <i>Acinetobacter baumannii</i> .....	63
1.1. Gram Stain and Microscope Examination.....	63
1.2. Vitek-2 System.....	64
2. Distribution of Gram-negative Isolates.....	65
3. Distribution of <i>Acinetobacter baumannii</i> Isolated from Different Clinical Specimens.....	66
4. Distribution of <i>Acinetobacter baumannii</i> Isolated per Gender.....	67

<b>5. Anti-biogram Analysis of <i>A. baumannii</i> Isolates Against some Antimicrobial Agents.....</b>	<b>68</b>
<b>5.1. Antimicrobial Susceptibility Test Disk Diffusion Method.....</b>	<b>69</b>
<b>5.2. Minimum Inhibitory Concentrations MICs.....</b>	<b>70</b>
<b>6. Molecular Characterization of Carbapenemase and 16S rRNA Methyltransferase Genes.....</b>	<b>73</b>
<b>7. Colistin Resistant Determinants.....</b>	<b>74</b>
<b>8. Sequencing.....</b>	<b>75</b>
<b>6. DISCUSSION.....</b>	<b>91</b>
<b>7. SUMMARY.....</b>	<b>101</b>
<b>8. REFERENCES .....</b>	<b>103</b>
<b>الملخص العربي</b>	<b>1</b>

# LIST OF ABBREVIATIONS

ABBREVIATIONS	Definition
A.b	<i>Acinetobacter baumannii</i>
ADCs	<i>Acinetobacter</i> -derived Cephalosporinase
AK	Amikacin
AAC	Aminoglycoside acetyltransferase
ANT	Aminoglycoside nucleotidyltransferase
APS	Aminoglycoside phosphotransferase
AMEs	Aminoglycoside-modifying enzymes
BaCl <sub>2</sub>	Barium chloride
BAP	Biofilm-associated protein
CRE	Carbapenem-resistant <i>Enterobacteriaceae</i>
CRAB	Carbapenem-resistant <i>Acinetobacter baumannii</i>
CAUTI	Catheter associated urinary tract infections
CTX	Cefotaxime
CLABSI	Central line-associated bloodstream infections
CNS	Central nervous system
CSF	Cerebrospinal fluid
CIP	Ciprofloxacin
CLSI	Clinical and Laboratory Standards Institute

## LIST OF ABBREVIATIONS

---

<b>CT</b>	<b>Colistin</b>
<b>CO</b>	<b>Co-trimoxazole</b>
<b>DO</b>	<b>Doxycycline</b>
<b>ESKAPE</b>	<i>Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.</i>
<b>EDTA</b>	<b>Ethylenediaminetetraacetic acid</b>
<b>EARS-NET</b>	<b>European antimicrobial resistance surveillance network</b>
<b>ESBL</b>	<b>Extended-spectrum Beta-lactamase</b>
<b>XDR</b>	<b>Extensive-drug resistance</b>
<b>FQ</b>	<b>Fluoroquinolone</b>
<b>FDA</b>	<b>Food and Drug Administration</b>
<b>CN</b>	<b>Gentamicin</b>
<b>GNB</b>	<b>Gram-negative Bacteria</b>
<b>HAI</b>	<b>Health care associated infections</b>
<b>HGT</b>	<b>Horizontal gene transfer</b>
<b>Imp</b>	<b>Imipenem</b>
<b>IS</b>	<b>Insertion sequence</b>
<b>ICU</b>	<b>Intensive Care Unite</b>
<b>LPS</b>	<b>Lipopolysaccharide</b>

## LIST OF ABBREVIATIONS

---

<b>MEM</b>	<b>Meropenem</b>
<b>MBLs</b>	<b>Metallo-Beta-lactamase</b>
<b>MIC</b>	<b>Minimum inhibitory concentration</b>
<b>MGEs</b>	<b>Mobile Genetic Elements</b>
<b>MHT</b>	<b>Modified Hodge Test</b>
<b>MH agar</b>	<b>Muller-Hinton Agar</b>
<b>MDR</b>	<b>Multi-Drug Resistant</b>
<b>OMPs</b>	<b>Outer membrane proteins</b>
<b>PAN</b>	<b>Pan-drug resistance</b>
<b>PBPs</b>	<b>Penicillin-binding proteins</b>
<b>KOH</b>	<b>Potassium hydroxide</b>
<b>RIF</b>	<b>Rifampicin</b>
<b>NaOH</b>	<b>Sodium hydroxide</b>
<b>H<sub>2</sub>SO<sub>4</sub></b>	<b>Sulphuric acid</b>
<b>SSI</b>	<b>Surgical site infections</b>
<b>TOB</b>	<b>Tobramycin</b>
<b>SXT</b>	<b>Trimethoprim-sulfamethoxazole</b>
<b>USA</b>	<b>United State of America</b>
<b>UTI</b>	<b>Urinary tract infection</b>
<b>VAP</b>	<b>Ventilator associated pneumonia</b>
<b>WHO</b>	<b>World Health Organization</b>



# LIST OF FIGURES

Table	Page Number
<b>Figure 1:</b> Definition of drug-resistant <i>Acinetobacter</i> species along with therapeutic options. Resistance promoting factors and Susceptibility controlling factors has been summarized.....	<b>44</b>
<b>Figure 2:</b> Gram stain of <i>A. baumannii</i> test Isolates showing Red Coccobacilli.....	<b>63</b>
<b>Figure 3:</b> Vitek 2-system, <i>A. baumannii</i> Identification Report.....	<b>64</b>
<b>Figure 4:</b> Distribution of Gram-Negative Isolates .....	<b>65</b>
<b>Figure 5:</b> Percentage Distribution of <i>A. baumannii</i> Isolates as per Source of Clinical Specimens .....	<b>66</b>
<b>Figure 6:</b> Percentage Distribution of <i>A. baumannii</i> Isolates per Gender.....	<b>67</b>
<b>Figure 7:</b> Results of Antimicrobial Susceptibility Testing Performed by the Disk Diffusion Method.....	<b>69</b>
<b>Figure 8:</b> Multiplex PCRs for detection of <i>blaOXA</i> carbapenemase genes...	<b>73</b>
<b>Figure 9:</b> Agarose Gel electrophoresis of <i>Acinetobacter baumannii</i> , PCR product isolate.....	<b>74</b>
<b>Figure 10:</b> Sequence chromatogram for A140 pmrC gene (Forward).....	<b>76</b>
<b>Figure 11:</b> Sequence chromatogram for A140 pmrC gene (Reverse).....	<b>77</b>
<b>Figure 12:</b> Protein alignment of PmrCA140 with ATCC19787.....	<b>79</b>
<b>Figure 13:</b> Sequence chromatogram for A140 pmrB gene (Forward).....	<b>80</b>
<b>Figure 14:</b> Sequence chromatogram for A140 pmrB gene (Reverse).....	<b>81</b>
<b>Figure 15:</b> Protein alignment of PmrBA140 with ATCC19787.....	<b>82</b>
<b>Figure 16:</b> Sequence chromatogram for A140 pmrA gene (Forward) .....	<b>83</b>
<b>Figure 17:</b> Sequence chromatogram for A140 pmrA gene (Reverse).....	<b>84</b>

## LIST OF FIGURES

---

<b>Figure 18:</b> Sequence chromatogram for A140 LpxA gene (Forward).....	<b>85</b>
<b>Figure 19:</b> Sequence chromatogram for A140 LpxA gene (Reverse).....	<b>86</b>
<b>Figure 20:</b> Sequence chromatogram for A140 LpsB gene (Forward).....	<b>87</b>
<b>Figure 21:</b> Sequence chromatogram for A140 LpsB gene (Reverse).....	<b>88</b>
<b>Figure 22:</b> Sequence chromatogram for A140 LpxC gene (forward).....	<b>89</b>
<b>Figure 23:</b> Sequence chromatogram for A140 LpxC gene (Reverse).....	<b>90</b>

## LIST OF TABLES

Table	Page Number
<b>Table 1.</b> Resistance rates of Gram-negative bacteria that causes ICU-acquired infections.....	<b>24</b>
<b>Table 2.</b> Mechanisms of antibiotic resistance found in <i>Acinetobacter</i> species Analysis of antibiotic resistance genes in multidrug-resistant <i>Acinetobacter</i> sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.....	<b>31</b>
<b>Table 3.</b> Different chemicals used in the present study and their sources.....	<b>46</b>
<b>Table 4.</b> Equipment used throughout this study .....	<b>53</b>
<b>Table 5.</b> kit content of DNeasy Blood & Tissue Kits (Qiagen).....	<b>57</b>
<b>Table 6.</b> Primers used in this Study.....	<b>60</b>
<b>Table 7.</b> Interpretation criteria for antimicrobial susceptibility testing of <i>A. baumannii</i> by disk diffusion method.....	<b>68</b>
<b>Table 8.</b> Results of MIC testing performed by the broth dilution method.....	<b>70</b>